The structural basis of protein acetylation by the p300/CBP transcriptional coactivator

Nature

Volumn 451, Issue 7180, 2008, Pages 846-850

  Liu, Xin ^a,b   Wang, Ling ^c   Zhao, Kehao ^a,d   Thompson, Paul R ^c,e   Hwang, Yousang ^c   Marmorstein, Ronen ^a,b   Cole, Philip A ^c  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; HISTONE ACETYLTRANSFERASE PCAF;

CANCER; CATALYSIS; ENZYME; EXPERIMENTAL STUDY; GENE EXPRESSION; MUTATION; PROTEIN;

ACETYLATION; ARTICLE; CRYSTAL STRUCTURE; ENZYME STRUCTURE; GENE EXPRESSION REGULATION; MUTAGENESIS; NEOPLASM; PRIORITY JOURNAL; SEQUENCE ALIGNMENT;

EID: 39149109887     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature06546     Document Type: Article

References (30)

1. Goodman, R. H. & Smolik, S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14, 1553-1577 (2000).
2. Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H. & Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 953-959 (1996).
3. Bannister, A. J. & Kouzarides, T. The CBP co-activator is a histone acetyltransferase. Nature 384, 641-643 (1996).
4. Iyer, N. G., Ozdag, H. & Caldas, C. p300/CBP and cancer. Oncogene 23, 4225-4231 (2004).
5. Martinez-Balbas, M. A. et al. The acetyltransferase activity of CBP stimulates transcription. EMBO J. 17, 2886-2893 (1998).
6. Yuan, L. W. & Giordano, A. Acetyltransferase machinery conserved in p300/ CBP-family proteins. Oncogene 21, 2253-2260 (2002).
7. Poux, A. N., Cebrat, M., Kim, C. M., Cole, P. A. & Marmorstein, R. Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc. Natl Acad. Sci. USA 99, 14065-14070 (2002).
8. Lau, O. D. et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell 5, 589-595 (2000).
9. Thompson, P. R., Kurooka, H., Nakatani, Y. & Cole, P. A. Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J. Biol. Chem. 276, 33721-33729 (2001).
10. Thompson, P. R. et al. Regulation of the p300 HAT domain via a novel activation loop. Nature Struct. Mol. Biol. 11, 308-315 (2004).
11. Karanam, B. et al. Multiple roles for acetylation in the interaction of p300 HAT with ATF-2. Biochemistry 46, 8207-8216 (2007).
12. Marmorstein, R. Structure of histone acetyltransferases. J. Mol. Biol. 311, 433-444 (2001).
13. Neuwald, A. F. & Landsman, D. GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem. Sci. 22, 154-155 (1997).
14. Cebrat, M., Kim, C. M., Thompson, P. R., Daugherty, M. & Cole, P. A. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg. Med. Chem. 11, 3307-3313 (2003).
15. Hwang, Y. et al. A selective chemical probe for coenzyme A-requiring enzymes. Angew. Chem. Int. Edn Engl. 46, 7621-7624 (2007).
16. Segel, I. Enzyme Kinetics (Wiley Interscience, New York, 1975).
17. Scheibner, K. A., De Angelis, J., Burley, S. K. & Cole, P. A. Investigation of the roles of catalytic residues in serotonin N-acetyltransferase. J. Biol. Chem. 277, 18118-18126 (2002).
18. Murata, T. et al. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. Hum. Mol. Genet. 10, 1071-1076 (2001).
19. Muraoka, M. et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12, 1565-1569 (1996).
20. Gayther, S. A. et al. Mutations truncating the EP300 acetylase in human cancers. Nature Genet. 24, 300-303 (2000).
21. Kishimoto, M. et al. Mutations and deletions of the CBP gene in human lung cancer. Clin. Cancer Res. 11, 512-519 (2005).
22. Zheng, Y. et al. Selective HAT inhibitors as mechanistic tools for protein acetylation. Methods Enzymol. 376, 188-199 (2004).
23. Stimson, L. et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol. Cancer Ther. 4, 1521-1532 (2005).
24. Iyer, N. G. et al. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc. Natl Acad. Sci. USA 101, 7386-7391 (2004).
25. Davidson, S. M. et al. The transcriptional coactivator p300 plays a critical role in the hypertrophic and protective pathways induced by phenylephrine in cardiac cells but is specific to the hypertrophic effect of urocortin. ChemBioChem 6, 162-170 (2005).
26. Zhou, X. Y. et al. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nature Med. 10, 633-637 (2004).
27. Varier, R. A. & Kundu, T. K. Chromatin modifications (acetylation/ deacetylation/ methylation) as new targets for HIV therapy. Curr. Pharm. Des. 12, 1975-1993 (2006).
28. Guidez, F. et al. Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol. Cell. Biol. 25, 5552-5566 (2005).
29. Zheng, Y. et al. Synthesis and evaluation of a potent and selective cell-permeable p300 histone acetyltransferase inhibitor. J. Am. Chem. Soc. 127, 17182-17183 (2005).
30. Qiao, Y., Molina, H., Pandey, A., Zhang, J. & Cole, P. A. Chemical rescue of a mutant enzyme in living cells. Science 311, 1293-1297 (2006).